Stem definition | Drug id | CAS RN |
---|---|---|
anti-inflammatory, isoxicam derivatives | 1676 | 71125-38-7 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
15 | mg | P |
15 | mg | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.20 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.71 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 97 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.15 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.12 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 13, 2000 | FDA | BOEHRINGER INGELHEIM |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rheumatoid arthritis | 231.49 | 9.92 | 806 | 84046 | 201744 | 50318528 |
Spinal column injury | 162.53 | 9.92 | 73 | 84779 | 1729 | 50518543 |
Synovial cyst | 154.24 | 9.92 | 120 | 84732 | 8046 | 50512226 |
Surgical failure | 150.25 | 9.92 | 57 | 84795 | 864 | 50519408 |
Psoriatic arthropathy | 143.85 | 9.92 | 272 | 84580 | 46760 | 50473512 |
Bronchitis chronic | 140.05 | 9.92 | 85 | 84767 | 3792 | 50516480 |
Ankylosing spondylitis | 139.05 | 9.92 | 107 | 84745 | 7058 | 50513214 |
Psoriasis | 122.52 | 9.92 | 321 | 84531 | 68679 | 50451593 |
Maternal exposure during pregnancy | 119.89 | 9.92 | 59 | 84793 | 159719 | 50360553 |
Pemphigus | 116.45 | 9.92 | 29 | 84823 | 120137 | 50400135 |
Accident | 115.90 | 9.92 | 84 | 84768 | 5057 | 50515215 |
Fibromyalgia | 106.52 | 9.92 | 234 | 84618 | 44744 | 50475528 |
Exposure during pregnancy | 103.11 | 9.92 | 37 | 84815 | 120978 | 50399294 |
Death | 101 | 9.92 | 250 | 84602 | 325129 | 50195143 |
Neck pain | 92.76 | 9.92 | 257 | 84595 | 56810 | 50463462 |
Glossodynia | 87.70 | 9.92 | 42 | 84810 | 115527 | 50404745 |
Arthralgia | 86.90 | 9.92 | 1119 | 83733 | 437583 | 50082689 |
Visual impairment | 86.87 | 9.92 | 282 | 84570 | 67993 | 50452279 |
Musculoskeletal stiffness | 86.39 | 9.92 | 435 | 84417 | 128046 | 50392226 |
Tenosynovitis stenosans | 86.14 | 9.92 | 51 | 84801 | 2173 | 50518099 |
Febrile neutropenia | 81.27 | 9.92 | 31 | 84821 | 97636 | 50422636 |
Neutropenia | 81.18 | 9.92 | 77 | 84775 | 147888 | 50372384 |
Synovial fluid analysis | 80.81 | 9.92 | 44 | 84808 | 1594 | 50518678 |
Pulmonary toxicity | 80.45 | 9.92 | 70 | 84782 | 5492 | 50514780 |
Breast cancer | 78.64 | 9.92 | 202 | 84650 | 42688 | 50477584 |
Tenosynovitis | 77.31 | 9.92 | 92 | 84760 | 10473 | 50509799 |
Pain in extremity | 75.75 | 9.92 | 744 | 84108 | 272121 | 50248151 |
Drug hypersensitivity | 75.42 | 9.92 | 696 | 84156 | 250314 | 50269958 |
Musculoskeletal pain | 75.20 | 9.92 | 279 | 84573 | 71898 | 50448374 |
Rheumatoid lung | 73.85 | 9.92 | 48 | 84804 | 2417 | 50517855 |
Linear IgA disease | 71.22 | 9.92 | 37 | 84815 | 1217 | 50519055 |
Joint range of motion decreased | 69.33 | 9.92 | 117 | 84735 | 18395 | 50501877 |
Product dose omission issue | 65.24 | 9.92 | 529 | 84323 | 183309 | 50336963 |
Neck surgery | 64.93 | 9.92 | 37 | 84815 | 1466 | 50518806 |
Dry eye | 62.85 | 9.92 | 155 | 84697 | 31940 | 50488332 |
Scleritis | 62.20 | 9.92 | 48 | 84804 | 3179 | 50517093 |
Antinuclear antibody positive | 62.11 | 9.92 | 64 | 84788 | 6208 | 50514064 |
Bone density decreased | 58.38 | 9.92 | 82 | 84770 | 10993 | 50509279 |
Toxicity to various agents | 57.79 | 9.92 | 174 | 84678 | 212325 | 50307947 |
Systemic lupus erythematosus | 57.33 | 9.92 | 92 | 84760 | 140530 | 50379742 |
Crepitations | 57.19 | 9.92 | 61 | 84791 | 6158 | 50514114 |
Hypotension | 57.00 | 9.92 | 203 | 84649 | 235266 | 50285006 |
Gait disturbance | 55.57 | 9.92 | 436 | 84416 | 149569 | 50370703 |
Reversible airways obstruction | 54.80 | 9.92 | 29 | 84823 | 991 | 50519281 |
Drug ineffective | 54.03 | 9.92 | 1773 | 83079 | 817560 | 49702712 |
Vital capacity decreased | 50.85 | 9.92 | 27 | 84825 | 929 | 50519343 |
Pericarditis | 49.24 | 9.92 | 36 | 84816 | 78653 | 50441619 |
Thrombocytopenia | 47.94 | 9.92 | 88 | 84764 | 127585 | 50392687 |
General physical health deterioration | 46.02 | 9.92 | 107 | 84745 | 142327 | 50377945 |
Sputum culture positive | 45.99 | 9.92 | 29 | 84823 | 1385 | 50518887 |
Off label use | 44.00 | 9.92 | 547 | 84305 | 473879 | 50046393 |
Bursitis | 43.44 | 9.92 | 107 | 84745 | 22028 | 50498244 |
Viral upper respiratory tract infection | 43.28 | 9.92 | 56 | 84796 | 6940 | 50513332 |
Impaired work ability | 43.06 | 9.92 | 80 | 84772 | 13560 | 50506712 |
Nodule | 41.99 | 9.92 | 90 | 84762 | 16913 | 50503359 |
Joint swelling | 41.97 | 9.92 | 610 | 84242 | 244676 | 50275596 |
Anti-cyclic citrullinated peptide antibody positive | 40.76 | 9.92 | 35 | 84817 | 70552 | 50449720 |
Photophobia | 40.51 | 9.92 | 82 | 84770 | 14805 | 50505467 |
Pleuritic pain | 40.38 | 9.92 | 52 | 84800 | 6414 | 50513858 |
Bronchial secretion retention | 39.39 | 9.92 | 27 | 84825 | 1486 | 50518786 |
Loss of personal independence in daily activities | 38.78 | 9.92 | 225 | 84627 | 69825 | 50450447 |
Abortion spontaneous | 38.70 | 9.92 | 11 | 84841 | 41761 | 50478511 |
Conjunctivitis | 38.21 | 9.92 | 84 | 84768 | 16061 | 50504211 |
Joint effusion | 38.18 | 9.92 | 74 | 84778 | 12947 | 50507325 |
Intervertebral disc degeneration | 37.65 | 9.92 | 75 | 84777 | 13386 | 50506886 |
Wound | 37.03 | 9.92 | 76 | 84776 | 105718 | 50414554 |
Folliculitis | 36.95 | 9.92 | 10 | 84842 | 39215 | 50481057 |
Cardiac failure | 36.73 | 9.92 | 44 | 84808 | 75996 | 50444276 |
Cushingoid | 36.22 | 9.92 | 50 | 84802 | 6595 | 50513677 |
Feeling jittery | 35.92 | 9.92 | 66 | 84786 | 11094 | 50509178 |
Muscle injury | 35.84 | 9.92 | 9 | 84843 | 37102 | 50483170 |
Malignant neoplasm progression | 35.55 | 9.92 | 37 | 84815 | 68087 | 50452185 |
Condition aggravated | 35.52 | 9.92 | 697 | 84155 | 296361 | 50223911 |
Septic shock | 34.68 | 9.92 | 27 | 84825 | 57148 | 50463124 |
Back pain | 34.06 | 9.92 | 538 | 84314 | 219492 | 50300780 |
Pancytopenia | 33.27 | 9.92 | 56 | 84796 | 83974 | 50436298 |
Flank pain | 33.06 | 9.92 | 70 | 84782 | 13045 | 50507227 |
Listless | 32.41 | 9.92 | 29 | 84823 | 2361 | 50517911 |
Drug abuse | 31.80 | 9.92 | 32 | 84820 | 59814 | 50460458 |
Injection site swelling | 31.31 | 9.92 | 146 | 84706 | 41627 | 50478645 |
Injection site pain | 30.84 | 9.92 | 303 | 84549 | 110721 | 50409551 |
Gastric ulcer | 30.77 | 9.92 | 92 | 84760 | 21213 | 50499059 |
Allergy to chemicals | 30.56 | 9.92 | 22 | 84830 | 1310 | 50518962 |
Tenderness | 30.53 | 9.92 | 84 | 84768 | 18481 | 50501791 |
Somatic delusion | 30.15 | 9.92 | 16 | 84836 | 550 | 50519722 |
Arthritis | 29.87 | 9.92 | 248 | 84604 | 86473 | 50433799 |
Osteoarthritis | 29.69 | 9.92 | 207 | 84645 | 68399 | 50451873 |
Peripheral swelling | 29.43 | 9.92 | 497 | 84355 | 205439 | 50314833 |
Premature delivery | 28.94 | 9.92 | 3 | 84849 | 23660 | 50496612 |
Dry mouth | 28.88 | 9.92 | 177 | 84675 | 56001 | 50464271 |
Ocular hyperaemia | 28.72 | 9.92 | 87 | 84765 | 20205 | 50500067 |
Pyrexia | 27.91 | 9.92 | 459 | 84393 | 379744 | 50140528 |
Disease progression | 27.86 | 9.92 | 76 | 84776 | 95790 | 50424482 |
Sleep disorder due to general medical condition, insomnia type | 27.83 | 9.92 | 9 | 84843 | 31438 | 50488834 |
Eye irritation | 27.64 | 9.92 | 77 | 84775 | 17063 | 50503209 |
Rheumatoid nodule | 27.62 | 9.92 | 64 | 84788 | 12671 | 50507601 |
Product use in unapproved indication | 27.22 | 9.92 | 101 | 84751 | 115718 | 50404554 |
Malaise | 27.00 | 9.92 | 745 | 84107 | 334787 | 50185485 |
Ischaemic gastritis | 26.96 | 9.92 | 5 | 84847 | 0 | 50520272 |
Spinal cord infection | 26.84 | 9.92 | 15 | 84837 | 572 | 50519700 |
Anaemia | 26.47 | 9.92 | 283 | 84569 | 252173 | 50268099 |
Pain | 25.28 | 9.92 | 1199 | 83653 | 577704 | 49942568 |
Surgery | 25.21 | 9.92 | 109 | 84743 | 30096 | 50490176 |
Hypoaesthesia | 25.20 | 9.92 | 325 | 84527 | 126932 | 50393340 |
Injection site erythema | 25.12 | 9.92 | 213 | 84639 | 74723 | 50445549 |
Infusion related reaction | 24.94 | 9.92 | 174 | 84678 | 169383 | 50350889 |
Hepatic enzyme increased | 24.91 | 9.92 | 132 | 84720 | 137248 | 50383024 |
Lymphomatoid papulosis | 24.91 | 9.92 | 9 | 84843 | 118 | 50520154 |
Pleural effusion | 24.86 | 9.92 | 63 | 84789 | 81391 | 50438881 |
Cholestasis | 24.84 | 9.92 | 6 | 84846 | 25395 | 50494877 |
Eye pain | 24.78 | 9.92 | 104 | 84748 | 28345 | 50491927 |
Acute kidney injury | 23.76 | 9.92 | 256 | 84596 | 227802 | 50292470 |
Pregnancy | 23.59 | 9.92 | 10 | 84842 | 29567 | 50490705 |
Depression | 23.54 | 9.92 | 399 | 84453 | 165024 | 50355248 |
Pulmonary mass | 23.53 | 9.92 | 77 | 84775 | 18628 | 50501644 |
Intentional self-injury | 23.52 | 9.92 | 5 | 84847 | 23107 | 50497165 |
Feeling abnormal | 23.39 | 9.92 | 317 | 84535 | 125175 | 50395097 |
Gastric ulcer haemorrhage | 23.33 | 9.92 | 33 | 84819 | 4451 | 50515821 |
Reduced facial expression | 22.93 | 9.92 | 20 | 84832 | 1574 | 50518698 |
Injection site reaction | 22.86 | 9.92 | 153 | 84699 | 49879 | 50470393 |
Infection | 22.06 | 9.92 | 410 | 84442 | 172544 | 50347728 |
Electrocardiogram QT prolonged | 22.03 | 9.92 | 33 | 84819 | 51853 | 50468419 |
Hyponatraemia | 21.84 | 9.92 | 85 | 84767 | 96054 | 50424218 |
Intentional overdose | 21.78 | 9.92 | 45 | 84807 | 62459 | 50457813 |
Pre-existing condition improved | 21.62 | 9.92 | 41 | 84811 | 7056 | 50513216 |
Head discomfort | 21.34 | 9.92 | 53 | 84799 | 10966 | 50509306 |
Musculoskeletal discomfort | 21.20 | 9.92 | 64 | 84788 | 14834 | 50505438 |
Bradycardia | 21.11 | 9.92 | 48 | 84804 | 64378 | 50455894 |
Pulmonary oedema | 20.90 | 9.92 | 31 | 84821 | 48907 | 50471365 |
Hypermobility syndrome | 20.88 | 9.92 | 14 | 84838 | 743 | 50519529 |
Premature baby | 20.77 | 9.92 | 3 | 84849 | 18334 | 50501938 |
Swelling | 20.71 | 9.92 | 226 | 84626 | 200646 | 50319626 |
Drug intolerance | 20.67 | 9.92 | 497 | 84355 | 218607 | 50301665 |
HLA marker study positive | 20.56 | 9.92 | 9 | 84843 | 200 | 50520072 |
Atelectasis | 20.17 | 9.92 | 72 | 84780 | 18198 | 50502074 |
Eyelid retraction | 19.95 | 9.92 | 6 | 84846 | 42 | 50520230 |
Interstitial lung disease | 19.90 | 9.92 | 155 | 84697 | 53021 | 50467251 |
Lower respiratory tract infection | 19.86 | 9.92 | 87 | 84765 | 95114 | 50425158 |
Oesophageal mucosal tear | 19.81 | 9.92 | 5 | 84847 | 16 | 50520256 |
Upper-airway cough syndrome | 19.68 | 9.92 | 44 | 84808 | 8506 | 50511766 |
Fixed eruption | 19.58 | 9.92 | 14 | 84838 | 825 | 50519447 |
Poliomyelitis | 19.48 | 9.92 | 6 | 84846 | 46 | 50520226 |
Neoplasm malignant | 19.35 | 9.92 | 85 | 84767 | 23630 | 50496642 |
Sedation | 19.15 | 9.92 | 14 | 84838 | 30596 | 50489676 |
Muscular weakness | 18.95 | 9.92 | 243 | 84609 | 94770 | 50425502 |
Vertigo | 18.80 | 9.92 | 150 | 84702 | 51682 | 50468590 |
Multiple organ dysfunction syndrome | 18.61 | 9.92 | 35 | 84817 | 50302 | 50469970 |
Carpal tunnel syndrome | 18.16 | 9.92 | 66 | 84786 | 16827 | 50503445 |
Gastric mucosal hypertrophy | 18.07 | 9.92 | 6 | 84846 | 60 | 50520212 |
Small intestinal ulcer haemorrhage | 17.89 | 9.92 | 6 | 84846 | 62 | 50520210 |
Foetal exposure during pregnancy | 17.79 | 9.92 | 12 | 84840 | 27347 | 50492925 |
Cataract | 17.77 | 9.92 | 138 | 84714 | 47162 | 50473110 |
Stress fracture | 17.68 | 9.92 | 37 | 84815 | 6838 | 50513434 |
Spinal operation | 17.65 | 9.92 | 35 | 84817 | 6225 | 50514047 |
Product use issue | 17.55 | 9.92 | 163 | 84689 | 149312 | 50370960 |
Nodular rash | 17.52 | 9.92 | 8 | 84844 | 197 | 50520075 |
Respiratory failure | 17.43 | 9.92 | 86 | 84766 | 91095 | 50429177 |
Hepatocellular injury | 17.39 | 9.92 | 11 | 84841 | 25936 | 50494336 |
Drug interaction | 17.37 | 9.92 | 233 | 84619 | 199388 | 50320884 |
Loss of consciousness | 16.82 | 9.92 | 257 | 84595 | 104096 | 50416176 |
Therapy cessation | 16.70 | 9.92 | 87 | 84765 | 25924 | 50494348 |
Mucosal inflammation | 16.59 | 9.92 | 26 | 84826 | 40116 | 50480156 |
Breast cancer female | 16.57 | 9.92 | 36 | 84816 | 6826 | 50513446 |
Rash pruritic | 16.56 | 9.92 | 137 | 84715 | 47709 | 50472563 |
Injection site bruising | 16.53 | 9.92 | 112 | 84740 | 36656 | 50483616 |
Pharyngeal paraesthesia | 16.40 | 9.92 | 16 | 84836 | 1453 | 50518819 |
Nephrolithiasis | 16.40 | 9.92 | 107 | 84745 | 34586 | 50485686 |
Injection site vesicles | 16.34 | 9.92 | 21 | 84831 | 2584 | 50517688 |
Urine odour abnormal | 16.32 | 9.92 | 31 | 84821 | 5342 | 50514930 |
Parotid gland enlargement | 16.26 | 9.92 | 12 | 84840 | 743 | 50519529 |
Sciatica | 16.22 | 9.92 | 75 | 84777 | 21307 | 50498965 |
Dyspnoea | 16.21 | 9.92 | 752 | 84100 | 546856 | 49973416 |
Affect lability | 16.09 | 9.92 | 42 | 84810 | 8956 | 50511316 |
Pulmonary arterial hypertension | 16.00 | 9.92 | 7 | 84845 | 20312 | 50499960 |
Tinnitus | 15.98 | 9.92 | 91 | 84761 | 28041 | 50492231 |
Agranulocytosis | 15.91 | 9.92 | 8 | 84844 | 21413 | 50498859 |
Gastrointestinal disorder | 15.89 | 9.92 | 93 | 84759 | 94363 | 50425909 |
Foreign body | 15.82 | 9.92 | 18 | 84834 | 1953 | 50518319 |
Leukopenia | 15.79 | 9.92 | 59 | 84793 | 67469 | 50452803 |
Device expulsion | 15.79 | 9.92 | 15 | 84837 | 28807 | 50491465 |
Multiple allergies | 15.65 | 9.92 | 40 | 84812 | 8423 | 50511849 |
Respiratory distress | 15.41 | 9.92 | 17 | 84835 | 30472 | 50489800 |
Eosinophilia | 15.37 | 9.92 | 6 | 84846 | 18646 | 50501626 |
Neutrophil count decreased | 15.32 | 9.92 | 34 | 84818 | 45992 | 50474280 |
Body temperature increased | 15.27 | 9.92 | 18 | 84834 | 31323 | 50488949 |
Distributive shock | 15.12 | 9.92 | 12 | 84840 | 828 | 50519444 |
Hepatotoxicity | 15.11 | 9.92 | 14 | 84838 | 27212 | 50493060 |
Dysphoria | 15.07 | 9.92 | 28 | 84824 | 4746 | 50515526 |
Mobility decreased | 14.91 | 9.92 | 202 | 84650 | 79746 | 50440526 |
Sacroiliitis | 14.85 | 9.92 | 20 | 84832 | 2577 | 50517695 |
Anhidrosis | 14.82 | 9.92 | 6 | 84846 | 109 | 50520163 |
Swelling face | 14.82 | 9.92 | 144 | 84708 | 52451 | 50467821 |
Contraindicated product administered | 14.79 | 9.92 | 169 | 84683 | 148789 | 50371483 |
Road traffic accident | 14.65 | 9.92 | 80 | 84772 | 24272 | 50496000 |
Duodenal ulcer | 14.64 | 9.92 | 34 | 84818 | 6741 | 50513531 |
Neutropenic sepsis | 14.52 | 9.92 | 3 | 84849 | 14144 | 50506128 |
Platelet count decreased | 14.49 | 9.92 | 104 | 84748 | 100622 | 50419650 |
Bone marrow failure | 14.41 | 9.92 | 15 | 84837 | 27609 | 50492663 |
Intervertebral disc protrusion | 14.35 | 9.92 | 70 | 84782 | 20323 | 50499949 |
Kyphoscoliosis | 14.05 | 9.92 | 9 | 84843 | 442 | 50519830 |
Ulcer | 13.98 | 9.92 | 69 | 84783 | 20131 | 50500141 |
Finger deformity | 13.94 | 9.92 | 30 | 84822 | 5652 | 50514620 |
Acute myeloid leukaemia | 13.90 | 9.92 | 4 | 84848 | 15070 | 50505202 |
Blood creatinine increased | 13.90 | 9.92 | 73 | 84779 | 76087 | 50444185 |
Tachycardia | 13.87 | 9.92 | 104 | 84748 | 99659 | 50420613 |
Small intestine ulcer | 13.77 | 9.92 | 8 | 84844 | 329 | 50519943 |
Coma | 13.75 | 9.92 | 49 | 84803 | 56830 | 50463442 |
Posterior reversible encephalopathy syndrome | 13.70 | 9.92 | 4 | 84848 | 14924 | 50505348 |
Ejection fraction decreased | 13.63 | 9.92 | 7 | 84845 | 18513 | 50501759 |
Suicide attempt | 13.58 | 9.92 | 43 | 84809 | 51689 | 50468583 |
Tubulointerstitial nephritis | 13.55 | 9.92 | 56 | 84796 | 15155 | 50505117 |
Haemorrhagic diathesis | 13.53 | 9.92 | 24 | 84828 | 3924 | 50516348 |
Spinal osteoarthritis | 13.45 | 9.92 | 53 | 84799 | 14039 | 50506233 |
Myofascial pain syndrome | 13.40 | 9.92 | 17 | 84835 | 2066 | 50518206 |
Lip swelling | 13.39 | 9.92 | 79 | 84773 | 24657 | 50495615 |
Jaundice neonatal | 13.36 | 9.92 | 11 | 84841 | 800 | 50519472 |
Asterixis | 13.35 | 9.92 | 13 | 84839 | 1178 | 50519094 |
Anxiety | 13.32 | 9.92 | 391 | 84461 | 177215 | 50343057 |
Chromaturia | 13.23 | 9.92 | 54 | 84798 | 14536 | 50505736 |
Thalassaemia minor | 13.18 | 9.92 | 4 | 84848 | 29 | 50520243 |
Meralgia paraesthetica | 13.17 | 9.92 | 6 | 84846 | 147 | 50520125 |
Limb asymmetry | 13.16 | 9.92 | 11 | 84841 | 817 | 50519455 |
Injection site warmth | 13.11 | 9.92 | 52 | 84800 | 13814 | 50506458 |
Hypercalcaemia | 12.97 | 9.92 | 12 | 84840 | 23340 | 50496932 |
Trigger finger | 12.95 | 9.92 | 23 | 84829 | 3765 | 50516507 |
Cytomegalovirus infection | 12.91 | 9.92 | 7 | 84845 | 17955 | 50502317 |
Pneumonia aspiration | 12.89 | 9.92 | 20 | 84832 | 30984 | 50489288 |
Urticaria | 12.86 | 9.92 | 147 | 84705 | 129414 | 50390858 |
Purpura senile | 12.74 | 9.92 | 9 | 84843 | 520 | 50519752 |
Intentional product misuse | 12.70 | 9.92 | 127 | 84725 | 46607 | 50473665 |
International normalised ratio increased | 12.69 | 9.92 | 34 | 84818 | 43118 | 50477154 |
Lumbar spinal stenosis | 12.66 | 9.92 | 24 | 84828 | 4130 | 50516142 |
Clostridium difficile colitis | 12.62 | 9.92 | 7 | 84845 | 17735 | 50502537 |
Dysstasia | 12.42 | 9.92 | 61 | 84791 | 17758 | 50502514 |
Hepatic cirrhosis | 12.41 | 9.92 | 7 | 84845 | 17570 | 50502702 |
Hypoxia | 12.39 | 9.92 | 44 | 84808 | 51079 | 50469193 |
Hepatic failure | 12.33 | 9.92 | 22 | 84830 | 32261 | 50488011 |
Therapy non-responder | 12.31 | 9.92 | 44 | 84808 | 50978 | 50469294 |
Focal segmental glomerulosclerosis | 12.06 | 9.92 | 13 | 84839 | 1328 | 50518944 |
Atopic keratoconjunctivitis | 12.03 | 9.92 | 3 | 84849 | 9 | 50520263 |
Duodenal ulcer perforation | 11.91 | 9.92 | 38 | 84814 | 45573 | 50474699 |
Joint stiffness | 11.70 | 9.92 | 89 | 84763 | 30219 | 50490053 |
Pelvic fracture | 11.54 | 9.92 | 44 | 84808 | 11476 | 50508796 |
Sputum culture | 11.35 | 9.92 | 5 | 84847 | 113 | 50520159 |
Pelvic adhesions | 11.32 | 9.92 | 7 | 84845 | 323 | 50519949 |
Influenza | 11.31 | 9.92 | 212 | 84640 | 89326 | 50430946 |
Crystal nephropathy | 11.27 | 9.92 | 10 | 84842 | 805 | 50519467 |
Resorption bone increased | 11.27 | 9.92 | 11 | 84841 | 1000 | 50519272 |
Helicobacter infection | 11.24 | 9.92 | 44 | 84808 | 49658 | 50470614 |
Confusional state | 11.24 | 9.92 | 232 | 84620 | 185696 | 50334576 |
General symptom | 11.19 | 9.92 | 17 | 84835 | 2446 | 50517826 |
Prescription drug used without a prescription | 11.13 | 9.92 | 14 | 84838 | 1686 | 50518586 |
Grip strength decreased | 11.10 | 9.92 | 45 | 84807 | 12076 | 50508196 |
Aerophagia | 11.00 | 9.92 | 3 | 84849 | 14 | 50520258 |
Small intestinal stenosis | 10.94 | 9.92 | 8 | 84844 | 488 | 50519784 |
Antinuclear antibody | 10.80 | 9.92 | 8 | 84844 | 498 | 50519774 |
Manipulation | 10.70 | 9.92 | 4 | 84848 | 58 | 50520214 |
Therapy interrupted | 10.67 | 9.92 | 64 | 84788 | 20088 | 50500184 |
Cholecystectomy | 10.56 | 9.92 | 37 | 84815 | 9266 | 50511006 |
Injury | 10.55 | 9.92 | 127 | 84725 | 48798 | 50471474 |
Lacrimation decreased | 10.53 | 9.92 | 7 | 84845 | 366 | 50519906 |
Wrong drug | 10.53 | 9.92 | 5 | 84847 | 135 | 50520137 |
Memory impairment | 10.41 | 9.92 | 189 | 84663 | 79171 | 50441101 |
Tarsal tunnel syndrome | 10.35 | 9.92 | 8 | 84844 | 531 | 50519741 |
Somnolence | 10.23 | 9.92 | 336 | 84516 | 154649 | 50365623 |
Hand deformity | 10.21 | 9.92 | 113 | 84739 | 100086 | 50420186 |
Neuroleptic malignant syndrome | 10.18 | 9.92 | 3 | 84849 | 11127 | 50509145 |
Foot fracture | 10.13 | 9.92 | 63 | 84789 | 20028 | 50500244 |
Myelosuppression | 10.11 | 9.92 | 5 | 84847 | 13512 | 50506760 |
Knee operation | 10.03 | 9.92 | 24 | 84828 | 4849 | 50515423 |
Hyperkalaemia | 9.99 | 9.92 | 44 | 84808 | 48045 | 50472227 |
Generalised tonic-clonic seizure | 9.98 | 9.92 | 18 | 84834 | 26292 | 50493980 |
Spinal cord herniation | 9.98 | 9.92 | 3 | 84849 | 21 | 50520251 |
Eosinophil count increased | 9.92 | 9.92 | 35 | 84817 | 8795 | 50511477 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 184.29 | 11.87 | 182 | 25990 | 32045 | 29516310 |
Psoriatic arthropathy | 101.14 | 11.87 | 92 | 26080 | 14599 | 29533756 |
Gastric haemorrhage | 77.64 | 11.87 | 65 | 26107 | 9232 | 29539123 |
Arthralgia | 76.42 | 11.87 | 284 | 25888 | 139333 | 29409022 |
Joint swelling | 64.08 | 11.87 | 138 | 26034 | 49492 | 29498863 |
Lipoma | 53.85 | 11.87 | 26 | 26146 | 1405 | 29546950 |
Pain | 49.97 | 11.87 | 290 | 25882 | 171142 | 29377213 |
Duodenal ulcer | 45.17 | 11.87 | 48 | 26124 | 9190 | 29539165 |
Ankylosing spondylitis | 45.17 | 11.87 | 34 | 26138 | 4142 | 29544213 |
Intestinal diaphragm disease | 44.35 | 11.87 | 14 | 26158 | 235 | 29548120 |
Seronegative arthritis | 41.59 | 11.87 | 19 | 26153 | 905 | 29547450 |
Neutropenia | 39.58 | 11.87 | 35 | 26137 | 131676 | 29416679 |
Off label use | 37.19 | 11.87 | 139 | 26033 | 300661 | 29247694 |
Osteoarthritis | 36.62 | 11.87 | 61 | 26111 | 18042 | 29530313 |
Xyphoid retraction | 36.18 | 11.87 | 11 | 26161 | 162 | 29548193 |
Febrile neutropenia | 35.97 | 11.87 | 28 | 26144 | 112212 | 29436143 |
Musculoskeletal stiffness | 35.13 | 11.87 | 92 | 26080 | 37366 | 29510989 |
Back pain | 35.10 | 11.87 | 181 | 25991 | 102103 | 29446252 |
Gastrointestinal haemorrhage | 34.01 | 11.87 | 150 | 26022 | 79383 | 29468972 |
Gastric ulcer | 33.42 | 11.87 | 51 | 26121 | 14010 | 29534345 |
Pain in extremity | 32.88 | 11.87 | 188 | 25984 | 110245 | 29438110 |
Product dose omission issue | 29.96 | 11.87 | 166 | 26006 | 96217 | 29452138 |
Thrombocytopenia | 28.63 | 11.87 | 47 | 26125 | 134776 | 29413579 |
Surgery | 28.38 | 11.87 | 43 | 26129 | 11736 | 29536619 |
Oesophageal infection | 27.30 | 11.87 | 10 | 26162 | 268 | 29548087 |
Arthropathy | 26.73 | 11.87 | 59 | 26113 | 21495 | 29526860 |
Rheumatoid arthritis | 26.19 | 11.87 | 75 | 26097 | 32077 | 29516278 |
Exostosis | 25.72 | 11.87 | 23 | 26149 | 3566 | 29544789 |
Arthritis | 24.01 | 11.87 | 62 | 26110 | 24957 | 29523398 |
Drug ineffective | 23.87 | 11.87 | 452 | 25720 | 362718 | 29185637 |
General physical health deterioration | 23.60 | 11.87 | 34 | 26138 | 102823 | 29445532 |
Inflammatory marker increased | 23.36 | 11.87 | 22 | 26150 | 3645 | 29544710 |
Oropharyngeal pain | 22.59 | 11.87 | 67 | 26105 | 29218 | 29519137 |
Injection site erythema | 21.77 | 11.87 | 42 | 26130 | 13914 | 29534441 |
Arthrofibrosis | 21.09 | 11.87 | 6 | 26166 | 69 | 29548286 |
Epstein Barr virus positive mucocutaneous ulcer | 19.72 | 11.87 | 8 | 26164 | 284 | 29548071 |
Finger deformity | 18.72 | 11.87 | 12 | 26160 | 1128 | 29547227 |
Multiple organ dysfunction syndrome | 18.66 | 11.87 | 17 | 26155 | 63099 | 29485256 |
Cartilage injury | 18.30 | 11.87 | 9 | 26163 | 506 | 29547849 |
Duodenal ulcer haemorrhage | 17.98 | 11.87 | 21 | 26151 | 4458 | 29543897 |
Drug hypersensitivity | 17.50 | 11.87 | 112 | 26060 | 68294 | 29480061 |
Hip arthroplasty | 17.44 | 11.87 | 19 | 26153 | 3739 | 29544616 |
Leukopenia | 17.38 | 11.87 | 14 | 26158 | 55189 | 29493166 |
Acute generalised exanthematous pustulosis | 17.32 | 11.87 | 23 | 26149 | 5560 | 29542795 |
Sinusitis | 17.17 | 11.87 | 68 | 26104 | 34282 | 29514073 |
Musculoskeletal discomfort | 16.50 | 11.87 | 24 | 26148 | 6317 | 29542038 |
Foot fracture | 16.49 | 11.87 | 19 | 26153 | 3976 | 29544379 |
Foot deformity | 16.41 | 11.87 | 19 | 26153 | 3996 | 29544359 |
Uveitis | 16.19 | 11.87 | 23 | 26149 | 5924 | 29542431 |
Macrophages increased | 16.10 | 11.87 | 6 | 26166 | 169 | 29548186 |
Electrocardiogram QRS complex prolonged | 16.05 | 11.87 | 19 | 26153 | 4091 | 29544264 |
Fixed eruption | 15.76 | 11.87 | 11 | 26161 | 1191 | 29547164 |
Cellulitis gangrenous | 15.53 | 11.87 | 6 | 26166 | 187 | 29548168 |
Hypokalaemia | 15.47 | 11.87 | 13 | 26159 | 50190 | 29498165 |
Skin ulcer | 15.39 | 11.87 | 44 | 26128 | 18796 | 29529559 |
Joint stiffness | 15.38 | 11.87 | 29 | 26143 | 9444 | 29538911 |
Iritis | 15.31 | 11.87 | 11 | 26161 | 1247 | 29547108 |
Ascites | 14.69 | 11.87 | 7 | 26165 | 36612 | 29511743 |
Injection site bruising | 14.60 | 11.87 | 25 | 26147 | 7555 | 29540800 |
Loose body in joint | 14.31 | 11.87 | 4 | 26168 | 43 | 29548312 |
Sleep apnoea syndrome | 14.27 | 11.87 | 41 | 26131 | 17558 | 29530797 |
Product physical issue | 14.21 | 11.87 | 13 | 26159 | 2075 | 29546280 |
Acanthosis | 14.17 | 11.87 | 5 | 26167 | 120 | 29548235 |
Tendon disorder | 14.15 | 11.87 | 14 | 26158 | 2464 | 29545891 |
Water intoxication | 14.10 | 11.87 | 7 | 26165 | 402 | 29547953 |
Hernia | 14.09 | 11.87 | 26 | 26146 | 8332 | 29540023 |
Skin exfoliation | 13.98 | 11.87 | 48 | 26124 | 22597 | 29525758 |
Fatigue | 13.73 | 11.87 | 372 | 25800 | 316449 | 29231906 |
Knee arthroplasty | 13.70 | 11.87 | 21 | 26151 | 5788 | 29542567 |
Duodenal ulcer perforation | 13.55 | 11.87 | 11 | 26161 | 1495 | 29546860 |
Intervertebral disc protrusion | 13.41 | 11.87 | 26 | 26146 | 8644 | 29539711 |
Headache | 13.29 | 11.87 | 222 | 25950 | 173785 | 29374570 |
Synovial cyst | 13.28 | 11.87 | 12 | 26160 | 1885 | 29546470 |
Grip strength decreased | 13.11 | 11.87 | 13 | 26159 | 2294 | 29546061 |
Prostatic specific antigen increased | 12.96 | 11.87 | 32 | 26140 | 12532 | 29535823 |
Eyelid margin crusting | 12.78 | 11.87 | 5 | 26167 | 161 | 29548194 |
Lumbar radiculopathy | 12.67 | 11.87 | 8 | 26164 | 733 | 29547622 |
Pyrexia | 12.63 | 11.87 | 179 | 25993 | 287443 | 29260912 |
Feeling abnormal | 12.62 | 11.87 | 87 | 26085 | 54358 | 29493997 |
Pulmonary tuberculosis | 12.21 | 11.87 | 17 | 26155 | 4298 | 29544057 |
Depression | 12.18 | 11.87 | 122 | 26050 | 85025 | 29463330 |
Peptic ulcer perforation | 12.11 | 11.87 | 5 | 26167 | 186 | 29548169 |
Neck surgery | 12.05 | 11.87 | 6 | 26166 | 347 | 29548008 |
Gastrointestinal injury | 12.03 | 11.87 | 6 | 26166 | 348 | 29548007 |
Peripheral swelling | 12.03 | 11.87 | 97 | 26075 | 63642 | 29484713 |
Joint space narrowing | 12.02 | 11.87 | 4 | 26168 | 80 | 29548275 |
Neck pain | 11.99 | 11.87 | 44 | 26128 | 21403 | 29526952 |
International normalised ratio increased | 11.91 | 11.87 | 13 | 26159 | 44359 | 29503996 |
Back disorder | 11.90 | 11.87 | 20 | 26152 | 5953 | 29542402 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Rheumatoid arthritis | 228.90 | 10.40 | 595 | 83287 | 163699 | 64251151 |
Psoriasis | 202.60 | 10.40 | 347 | 83535 | 71356 | 64343494 |
Psoriatic arthropathy | 200.55 | 10.40 | 264 | 83618 | 43017 | 64371833 |
Arthralgia | 161.55 | 10.40 | 1055 | 82827 | 441205 | 63973645 |
Surgical failure | 160.39 | 10.40 | 54 | 83828 | 745 | 64414105 |
Synovial cyst | 156.45 | 10.40 | 107 | 83775 | 7600 | 64407250 |
Neutropenia | 128.72 | 10.40 | 76 | 83806 | 239548 | 64175302 |
Ankylosing spondylitis | 127.51 | 10.40 | 97 | 83785 | 8137 | 64406713 |
Fibromyalgia | 124.16 | 10.40 | 190 | 83692 | 35541 | 64379309 |
Joint swelling | 122.80 | 10.40 | 580 | 83302 | 214802 | 64200048 |
Musculoskeletal stiffness | 117.46 | 10.40 | 390 | 83492 | 122816 | 64292034 |
Febrile neutropenia | 113.43 | 10.40 | 51 | 83831 | 187606 | 64227244 |
Drug hypersensitivity | 112.78 | 10.40 | 608 | 83274 | 237207 | 64177643 |
Pain in extremity | 109.19 | 10.40 | 721 | 83161 | 302364 | 64112486 |
Pain | 104.09 | 10.40 | 1138 | 82744 | 552373 | 63862477 |
Spinal column injury | 104.07 | 10.40 | 50 | 83832 | 1802 | 64413048 |
Bronchitis chronic | 100.34 | 10.40 | 63 | 83819 | 3869 | 64410981 |
Tenosynovitis stenosans | 95.47 | 10.40 | 48 | 83834 | 1912 | 64412938 |
Thrombocytopenia | 88.81 | 10.40 | 96 | 83786 | 223705 | 64191145 |
Synovial fluid analysis | 87.08 | 10.40 | 42 | 83840 | 1527 | 64413323 |
Neck pain | 81.62 | 10.40 | 219 | 83663 | 61314 | 64353536 |
Rheumatoid lung | 79.50 | 10.40 | 46 | 83836 | 2433 | 64412417 |
Death | 79.15 | 10.40 | 341 | 83541 | 482364 | 63932486 |
Musculoskeletal pain | 78.03 | 10.40 | 258 | 83624 | 81036 | 64333814 |
Accident | 75.14 | 10.40 | 66 | 83816 | 6780 | 64408070 |
Neck surgery | 73.86 | 10.40 | 37 | 83845 | 1462 | 64413388 |
Product dose omission issue | 72.29 | 10.40 | 467 | 83415 | 194280 | 64220570 |
Scleritis | 71.89 | 10.40 | 46 | 83836 | 2920 | 64411930 |
Joint range of motion decreased | 71.66 | 10.40 | 106 | 83776 | 19237 | 64395613 |
Hypotension | 68.80 | 10.40 | 259 | 83623 | 380715 | 64034135 |
Dry eye | 68.58 | 10.40 | 130 | 83752 | 28889 | 64385961 |
Drug ineffective | 62.30 | 10.40 | 1479 | 82403 | 838768 | 63576082 |
Bursitis | 61.98 | 10.40 | 105 | 83777 | 21380 | 64393470 |
Back pain | 60.25 | 10.40 | 542 | 83340 | 249629 | 64165221 |
Visual impairment | 59.76 | 10.40 | 222 | 83660 | 73855 | 64340995 |
Off label use | 59.38 | 10.40 | 532 | 83350 | 632274 | 63782576 |
Bone density decreased | 57.77 | 10.40 | 68 | 83814 | 9884 | 64404966 |
General physical health deterioration | 56.32 | 10.40 | 113 | 83769 | 204312 | 64210538 |
Septic shock | 55.77 | 10.40 | 34 | 83848 | 105403 | 64309447 |
Reversible airways obstruction | 52.89 | 10.40 | 27 | 83855 | 1111 | 64413739 |
Linear IgA disease | 52.75 | 10.40 | 37 | 83845 | 2737 | 64412113 |
Peripheral swelling | 51.29 | 10.40 | 455 | 83427 | 208698 | 64206152 |
Osteoarthritis | 51.24 | 10.40 | 190 | 83692 | 63146 | 64351704 |
Injection site erythema | 51.23 | 10.40 | 205 | 83677 | 70595 | 64344255 |
Pulmonary toxicity | 50.53 | 10.40 | 59 | 83823 | 8502 | 64406348 |
Vital capacity decreased | 48.56 | 10.40 | 25 | 83857 | 1047 | 64413803 |
Pancytopenia | 47.91 | 10.40 | 70 | 83812 | 143239 | 64271611 |
Acute kidney injury | 47.83 | 10.40 | 365 | 83517 | 448875 | 63965975 |
Antinuclear antibody positive | 47.17 | 10.40 | 49 | 83833 | 6201 | 64408649 |
Multiple organ dysfunction syndrome | 46.66 | 10.40 | 38 | 83844 | 101375 | 64313475 |
Toxicity to various agents | 46.32 | 10.40 | 280 | 83602 | 363233 | 64051617 |
Impaired work ability | 46.06 | 10.40 | 76 | 83806 | 15143 | 64399707 |
Joint effusion | 45.88 | 10.40 | 71 | 83811 | 13402 | 64401448 |
Nodule | 45.66 | 10.40 | 83 | 83799 | 17864 | 64396986 |
Intestinal diaphragm disease | 45.00 | 10.40 | 17 | 83865 | 333 | 64414517 |
Gastric ulcer | 44.59 | 10.40 | 112 | 83770 | 30122 | 64384728 |
Duodenal ulcer | 43.58 | 10.40 | 72 | 83810 | 14363 | 64400487 |
Arthritis | 43.57 | 10.40 | 220 | 83662 | 83594 | 64331256 |
Feeling jittery | 43.37 | 10.40 | 61 | 83821 | 10574 | 64404276 |
Feeling abnormal | 43.34 | 10.40 | 310 | 83572 | 133292 | 64281558 |
Gastric haemorrhage | 43.08 | 10.40 | 69 | 83813 | 13412 | 64401438 |
Injection site swelling | 43.07 | 10.40 | 135 | 83747 | 41218 | 64373632 |
Tenosynovitis | 42.62 | 10.40 | 64 | 83818 | 11769 | 64403081 |
Anaemia | 41.55 | 10.40 | 305 | 83577 | 378375 | 64036475 |
Photophobia | 41.51 | 10.40 | 78 | 83804 | 17215 | 64397635 |
Pyrexia | 41.14 | 10.40 | 497 | 83385 | 558147 | 63856703 |
Drug abuse | 41.06 | 10.40 | 68 | 83814 | 132306 | 64282544 |
Conjunctivitis | 40.65 | 10.40 | 85 | 83797 | 20269 | 64394581 |
Pleuritic pain | 40.00 | 10.40 | 51 | 83831 | 8045 | 64406805 |
Viral upper respiratory tract infection | 39.41 | 10.40 | 51 | 83831 | 8164 | 64406686 |
Gait disturbance | 39.38 | 10.40 | 369 | 83513 | 171786 | 64243064 |
Injection site pain | 39.37 | 10.40 | 264 | 83618 | 111144 | 64303706 |
Crepitations | 39.33 | 10.40 | 50 | 83832 | 7865 | 64406985 |
Tenderness | 39.31 | 10.40 | 82 | 83800 | 19520 | 64395330 |
Lipoma | 38.88 | 10.40 | 30 | 83852 | 2569 | 64412281 |
Leukopenia | 38.40 | 10.40 | 45 | 83837 | 101197 | 64313653 |
Cardiac failure | 38.33 | 10.40 | 71 | 83811 | 132302 | 64282548 |
Cushingoid | 37.73 | 10.40 | 48 | 83834 | 7555 | 64407295 |
Injection site reaction | 36.92 | 10.40 | 139 | 83743 | 46525 | 64368325 |
Musculoskeletal discomfort | 36.11 | 10.40 | 71 | 83811 | 16206 | 64398644 |
Therapeutic product effect decreased | 35.88 | 10.40 | 265 | 83617 | 115086 | 64299764 |
Exposure during pregnancy | 35.86 | 10.40 | 29 | 83853 | 77646 | 64337204 |
Mobility decreased | 35.66 | 10.40 | 212 | 83670 | 85628 | 64329222 |
Intervertebral disc degeneration | 35.07 | 10.40 | 62 | 83820 | 13058 | 64401792 |
Maternal exposure during pregnancy | 34.90 | 10.40 | 44 | 83838 | 95840 | 64319010 |
Listless | 34.67 | 10.40 | 31 | 83851 | 3259 | 64411591 |
Product use in unapproved indication | 34.53 | 10.40 | 116 | 83766 | 176502 | 64238348 |
Drug intolerance | 34.43 | 10.40 | 385 | 83497 | 187607 | 64227243 |
Malignant neoplasm progression | 34.06 | 10.40 | 59 | 83823 | 112812 | 64302038 |
Injection site bruising | 33.61 | 10.40 | 114 | 83768 | 36259 | 64378591 |
Sputum culture positive | 32.86 | 10.40 | 29 | 83853 | 2997 | 64411853 |
Bradycardia | 32.83 | 10.40 | 65 | 83817 | 118154 | 64296696 |
Flank pain | 32.79 | 10.40 | 68 | 83814 | 16121 | 64398729 |
Carpal tunnel syndrome | 32.67 | 10.40 | 67 | 83815 | 15761 | 64399089 |
Eye irritation | 32.59 | 10.40 | 67 | 83815 | 15789 | 64399061 |
Xyphoid retraction | 32.01 | 10.40 | 11 | 83871 | 162 | 64414688 |
Drug interaction | 31.45 | 10.40 | 310 | 83572 | 361773 | 64053077 |
Somatic delusion | 30.99 | 10.40 | 16 | 83866 | 674 | 64414176 |
Hyponatraemia | 30.68 | 10.40 | 95 | 83787 | 148244 | 64266606 |
Platelet count decreased | 30.21 | 10.40 | 114 | 83768 | 167597 | 64247253 |
Therapy cessation | 30.17 | 10.40 | 102 | 83780 | 32387 | 64382463 |
Hypermobility syndrome | 29.10 | 10.40 | 14 | 83868 | 506 | 64414344 |
Bronchial secretion retention | 29.02 | 10.40 | 25 | 83857 | 2502 | 64412348 |
Tachycardia | 28.71 | 10.40 | 99 | 83783 | 149480 | 64265370 |
Hypoaesthesia | 27.83 | 10.40 | 290 | 83592 | 138818 | 64276032 |
Arthrofibrosis | 27.80 | 10.40 | 9 | 83873 | 109 | 64414741 |
Depression | 27.71 | 10.40 | 362 | 83520 | 182929 | 64231921 |
Ocular hyperaemia | 27.61 | 10.40 | 78 | 83804 | 22486 | 64392364 |
Electrocardiogram QT prolonged | 27.34 | 10.40 | 38 | 83844 | 79410 | 64335440 |
Disease progression | 27.04 | 10.40 | 94 | 83788 | 141586 | 64273264 |
Headache | 26.93 | 10.40 | 889 | 82993 | 528578 | 63886272 |
Cardiogenic shock | 26.52 | 10.40 | 5 | 83877 | 32422 | 64382428 |
Fixed eruption | 26.10 | 10.40 | 22 | 83860 | 2137 | 64412713 |
Cytomegalovirus infection | 25.99 | 10.40 | 8 | 83874 | 37191 | 64377659 |
Sepsis | 25.96 | 10.40 | 184 | 83698 | 230157 | 64184693 |
Oropharyngeal pain | 25.85 | 10.40 | 201 | 83681 | 88666 | 64326184 |
Mucosal inflammation | 25.74 | 10.40 | 26 | 83856 | 62558 | 64352292 |
Small intestinal stenosis | 25.73 | 10.40 | 14 | 83868 | 657 | 64414193 |
Drug resistance | 25.53 | 10.40 | 7 | 83875 | 35095 | 64379755 |
Pleural effusion | 24.81 | 10.40 | 83 | 83799 | 126476 | 64288374 |
Foot fracture | 24.44 | 10.40 | 65 | 83817 | 18092 | 64396758 |
Head discomfort | 24.31 | 10.40 | 50 | 83832 | 11784 | 64403066 |
Neoplasm malignant | 24.25 | 10.40 | 79 | 83803 | 24609 | 64390241 |
International normalised ratio increased | 24.23 | 10.40 | 41 | 83841 | 79126 | 64335724 |
Hypoxia | 24.02 | 10.40 | 49 | 83833 | 88100 | 64326750 |
Road traffic accident | 23.84 | 10.40 | 91 | 83791 | 30654 | 64384196 |
Sciatica | 23.78 | 10.40 | 69 | 83813 | 20195 | 64394655 |
Therapeutic product effect incomplete | 23.74 | 10.40 | 222 | 83660 | 103260 | 64311590 |
Arthropathy | 23.63 | 10.40 | 251 | 83631 | 120716 | 64294134 |
Seronegative arthritis | 23.43 | 10.40 | 23 | 83859 | 2720 | 64412130 |
Hepatocellular injury | 23.34 | 10.40 | 15 | 83867 | 45220 | 64369630 |
Urine odour abnormal | 23.27 | 10.40 | 31 | 83851 | 5105 | 64409745 |
Breast cancer | 23.20 | 10.40 | 87 | 83795 | 29061 | 64385789 |
Hyperkalaemia | 22.92 | 10.40 | 62 | 83820 | 101067 | 64313783 |
Neurotoxicity | 22.90 | 10.40 | 4 | 83878 | 27400 | 64387450 |
Pulmonary mass | 22.83 | 10.40 | 76 | 83806 | 23940 | 64390910 |
Iritis | 22.75 | 10.40 | 24 | 83858 | 3092 | 64411758 |
Dry mouth | 22.44 | 10.40 | 145 | 83737 | 60273 | 64354577 |
Ischaemic gastritis | 22.43 | 10.40 | 5 | 83877 | 11 | 64414839 |
Sinusitis | 22.38 | 10.40 | 289 | 83593 | 145639 | 64269211 |
Injection site vesicles | 22.30 | 10.40 | 22 | 83860 | 2618 | 64412232 |
Eyelid retraction | 22.25 | 10.40 | 6 | 83876 | 36 | 64414814 |
Cataract | 22.19 | 10.40 | 128 | 83754 | 51134 | 64363716 |
Agranulocytosis | 22.13 | 10.40 | 11 | 83871 | 38218 | 64376632 |
Blood creatinine increased | 22.12 | 10.40 | 96 | 83786 | 135686 | 64279164 |
Rheumatoid nodule | 22.04 | 10.40 | 50 | 83832 | 12601 | 64402249 |
Bone marrow failure | 22.01 | 10.40 | 18 | 83864 | 47934 | 64366916 |
Hypoglycaemia | 22.00 | 10.40 | 53 | 83829 | 89839 | 64325011 |
Pemphigus | 21.94 | 10.40 | 28 | 83854 | 60673 | 64354177 |
Upper-airway cough syndrome | 21.60 | 10.40 | 40 | 83842 | 8730 | 64406120 |
Injection site pruritus | 21.59 | 10.40 | 102 | 83780 | 37724 | 64377126 |
Finger deformity | 21.52 | 10.40 | 30 | 83852 | 5156 | 64409694 |
Surgery | 21.46 | 10.40 | 83 | 83799 | 28130 | 64386720 |
Poliomyelitis | 20.87 | 10.40 | 6 | 83876 | 47 | 64414803 |
Intentional self-injury | 20.74 | 10.40 | 6 | 83876 | 29038 | 64385812 |
Hepatic failure | 20.60 | 10.40 | 25 | 83857 | 55369 | 64359481 |
Respiratory failure | 20.56 | 10.40 | 124 | 83758 | 161059 | 64253791 |
Spinal operation | 20.44 | 10.40 | 32 | 83850 | 6101 | 64408749 |
Cholestasis | 20.40 | 10.40 | 17 | 83865 | 44855 | 64369995 |
Pulmonary oedema | 20.37 | 10.40 | 45 | 83837 | 78629 | 64336221 |
Multiple allergies | 20.30 | 10.40 | 31 | 83851 | 5783 | 64409067 |
Neutrophil count decreased | 20.12 | 10.40 | 44 | 83838 | 77152 | 64337698 |
Eye pain | 20.08 | 10.40 | 88 | 83794 | 31537 | 64383313 |
Posterior reversible encephalopathy syndrome | 19.95 | 10.40 | 3 | 83879 | 22943 | 64391907 |
Exostosis | 19.69 | 10.40 | 45 | 83837 | 11393 | 64403457 |
Rhabdomyolysis | 19.49 | 10.40 | 58 | 83824 | 91668 | 64323182 |
Limb asymmetry | 19.43 | 10.40 | 11 | 83871 | 558 | 64414292 |
Blood bilirubin increased | 19.33 | 10.40 | 28 | 83854 | 57525 | 64357325 |
Intentional overdose | 19.02 | 10.40 | 57 | 83825 | 89887 | 64324963 |
Loss of personal independence in daily activities | 18.97 | 10.40 | 160 | 83722 | 72294 | 64342556 |
Lymphomatoid papulosis | 18.92 | 10.40 | 9 | 83873 | 317 | 64414533 |
Joint stiffness | 18.85 | 10.40 | 84 | 83798 | 30320 | 64384530 |
Pneumonia aspiration | 18.79 | 10.40 | 30 | 83852 | 59241 | 64355609 |
Clostridium difficile colitis | 18.76 | 10.40 | 6 | 83876 | 27217 | 64387633 |
Reduced facial expression | 18.58 | 10.40 | 18 | 83864 | 2095 | 64412755 |
Intervertebral disc protrusion | 18.40 | 10.40 | 63 | 83819 | 20128 | 64394722 |
Hepatotoxicity | 18.34 | 10.40 | 15 | 83867 | 39947 | 64374903 |
Right ventricular failure | 18.24 | 10.40 | 3 | 83879 | 21468 | 64393382 |
Foot deformity | 18.22 | 10.40 | 55 | 83827 | 16449 | 64398401 |
Gastrointestinal haemorrhage | 18.21 | 10.40 | 257 | 83625 | 132055 | 64282795 |
Ascites | 18.17 | 10.40 | 33 | 83849 | 61968 | 64352882 |
Manipulation | 18.15 | 10.40 | 6 | 83876 | 78 | 64414772 |
Respiratory distress | 18.03 | 10.40 | 25 | 83857 | 52306 | 64362544 |
Vertigo | 18.01 | 10.40 | 135 | 83747 | 58876 | 64355974 |
Injection site warmth | 17.92 | 10.40 | 48 | 83834 | 13414 | 64401436 |
Allergy to chemicals | 17.81 | 10.40 | 13 | 83869 | 1024 | 64413826 |
Malaise | 17.06 | 10.40 | 653 | 83229 | 395594 | 64019256 |
Oesophageal infection | 17.04 | 10.40 | 10 | 83872 | 543 | 64414307 |
Stress fracture | 16.90 | 10.40 | 28 | 83854 | 5596 | 64409254 |
Eosinophilia | 16.61 | 10.40 | 15 | 83867 | 38061 | 64376789 |
Sacroiliitis | 16.53 | 10.40 | 20 | 83862 | 2992 | 64411858 |
Blood creatine phosphokinase increased | 16.42 | 10.40 | 32 | 83850 | 58526 | 64356324 |
Oesophageal mucosal tear | 16.37 | 10.40 | 4 | 83878 | 15 | 64414835 |
Pharyngeal paraesthesia | 16.24 | 10.40 | 16 | 83866 | 1901 | 64412949 |
Nodular rash | 16.07 | 10.40 | 8 | 83874 | 312 | 64414538 |
Hypokalaemia | 15.96 | 10.40 | 93 | 83789 | 121810 | 64293040 |
Tumour lysis syndrome | 15.89 | 10.40 | 3 | 83879 | 19437 | 64395413 |
Cardiac failure congestive | 15.85 | 10.40 | 102 | 83780 | 130478 | 64284372 |
Grip strength decreased | 15.81 | 10.40 | 42 | 83840 | 11682 | 64403168 |
Tendon disorder | 15.75 | 10.40 | 29 | 83853 | 6303 | 64408547 |
Knee operation | 15.50 | 10.40 | 24 | 83858 | 4533 | 64410317 |
Pneumonitis | 15.49 | 10.40 | 26 | 83856 | 50339 | 64364511 |
Bronchopulmonary aspergillosis | 15.48 | 10.40 | 3 | 83879 | 19082 | 64395768 |
Hypercalcaemia | 15.43 | 10.40 | 11 | 83871 | 31405 | 64383445 |
Haematuria | 15.32 | 10.40 | 35 | 83847 | 60436 | 64354414 |
Tarsal tunnel syndrome | 15.22 | 10.40 | 9 | 83873 | 496 | 64414354 |
Atelectasis | 15.18 | 10.40 | 73 | 83809 | 27193 | 64387657 |
Glossodynia | 15.16 | 10.40 | 39 | 83843 | 64657 | 64350193 |
Aggression | 15.03 | 10.40 | 23 | 83859 | 46209 | 64368641 |
Abortion spontaneous | 14.91 | 10.40 | 7 | 83875 | 25136 | 64389714 |
Cartilage injury | 14.88 | 10.40 | 13 | 83869 | 1326 | 64413524 |
Arthritis infective | 14.79 | 10.40 | 30 | 83852 | 7000 | 64407850 |
Neuroleptic malignant syndrome | 14.76 | 10.40 | 7 | 83875 | 24989 | 64389861 |
Memory impairment | 14.55 | 10.40 | 173 | 83709 | 85509 | 64329341 |
Muscle spasms | 14.53 | 10.40 | 261 | 83621 | 140762 | 64274088 |
Epistaxis | 14.43 | 10.40 | 72 | 83810 | 98059 | 64316791 |
Chromaturia | 14.42 | 10.40 | 63 | 83819 | 22548 | 64392302 |
Pericarditis | 14.41 | 10.40 | 38 | 83844 | 62478 | 64352372 |
Thalassaemia minor | 14.18 | 10.40 | 4 | 83878 | 29 | 64414821 |
Knee arthroplasty | 14.11 | 10.40 | 71 | 83811 | 26928 | 64387922 |
Dizziness | 14.06 | 10.40 | 689 | 83193 | 429474 | 63985376 |
Syncope | 14.06 | 10.40 | 134 | 83748 | 157501 | 64257349 |
Cellulitis gangrenous | 14.06 | 10.40 | 7 | 83875 | 273 | 64414577 |
Trigger finger | 13.96 | 10.40 | 20 | 83862 | 3525 | 64411325 |
Muscular weakness | 13.95 | 10.40 | 238 | 83644 | 127100 | 64287750 |
Hepatic encephalopathy | 13.90 | 10.40 | 5 | 83877 | 21061 | 64393789 |
Pelvic adhesions | 13.71 | 10.40 | 7 | 83875 | 288 | 64414562 |
Pulmonary arterial hypertension | 13.66 | 10.40 | 8 | 83874 | 25359 | 64389491 |
Rash pruritic | 13.59 | 10.40 | 124 | 83758 | 57280 | 64357570 |
Myelosuppression | 13.58 | 10.40 | 7 | 83875 | 23823 | 64391027 |
Antinuclear antibody | 13.51 | 10.40 | 8 | 83874 | 442 | 64414408 |
Influenza | 13.50 | 10.40 | 204 | 83678 | 106327 | 64308523 |
Device related infection | 13.44 | 10.40 | 12 | 83870 | 30614 | 64384236 |
Cerebral haemorrhage | 13.41 | 10.40 | 29 | 83853 | 51061 | 64363789 |
Nephrolithiasis | 13.37 | 10.40 | 100 | 83782 | 43583 | 64371267 |
Duodenal ulcer haemorrhage | 13.32 | 10.40 | 27 | 83855 | 6298 | 64408552 |
Upper respiratory tract infection | 13.27 | 10.40 | 149 | 83733 | 72636 | 64342214 |
Rheumatic fever | 13.25 | 10.40 | 34 | 83848 | 9260 | 64405590 |
Seizure | 13.19 | 10.40 | 146 | 83736 | 166746 | 64248104 |
Sedation | 13.13 | 10.40 | 21 | 83861 | 41441 | 64373409 |
Rotator cuff syndrome | 13.04 | 10.40 | 40 | 83842 | 12067 | 64402783 |
Macrophages increased | 12.95 | 10.40 | 6 | 83876 | 199 | 64414651 |
Suicide attempt | 12.95 | 10.40 | 48 | 83834 | 70959 | 64343891 |
Treatment noncompliance | 12.87 | 10.40 | 23 | 83859 | 43459 | 64371391 |
Foreign body | 12.86 | 10.40 | 16 | 83866 | 2463 | 64412387 |
Abdominal pain upper | 12.80 | 10.40 | 308 | 83574 | 174722 | 64240128 |
Hyperglycaemia | 12.63 | 10.40 | 39 | 83843 | 60929 | 64353921 |
Small intestinal ulcer haemorrhage | 12.61 | 10.40 | 5 | 83877 | 112 | 64414738 |
Progressive multifocal leukoencephalopathy | 12.60 | 10.40 | 4 | 83878 | 18228 | 64396622 |
Purpura senile | 12.57 | 10.40 | 8 | 83874 | 503 | 64414347 |
Bacteraemia | 12.48 | 10.40 | 10 | 83872 | 26901 | 64387949 |
Renal failure | 12.43 | 10.40 | 164 | 83718 | 181524 | 64233326 |
Aspergillus infection | 12.42 | 10.40 | 3 | 83879 | 16376 | 64398474 |
Pelvic fracture | 12.42 | 10.40 | 36 | 83846 | 10527 | 64404323 |
Neuralgia | 12.40 | 10.40 | 67 | 83815 | 26117 | 64388733 |
Ulcer | 12.40 | 10.40 | 61 | 83821 | 22929 | 64391921 |
Anhidrosis | 12.39 | 10.40 | 6 | 83876 | 220 | 64414630 |
Abnormal faeces | 12.33 | 10.40 | 25 | 83857 | 5834 | 64409016 |
Subdural haematoma | 12.30 | 10.40 | 11 | 83871 | 28043 | 64386807 |
Fatigue | 12.22 | 10.40 | 1131 | 82751 | 747599 | 63667251 |
Body temperature increased | 12.15 | 10.40 | 18 | 83864 | 36648 | 64378202 |
Injection site urticaria | 12.10 | 10.40 | 37 | 83845 | 11144 | 64403706 |
Gastric mucosal hypertrophy | 12.10 | 10.40 | 6 | 83876 | 232 | 64414618 |
Muscle injury | 12.04 | 10.40 | 10 | 83872 | 26427 | 64388423 |
Affect lability | 11.91 | 10.40 | 32 | 83850 | 8958 | 64405892 |
Sleep disorder due to general medical condition, insomnia type | 11.88 | 10.40 | 10 | 83872 | 26260 | 64388590 |
Orthostatic hypotension | 11.88 | 10.40 | 27 | 83855 | 46711 | 64368139 |
Gastric ulcer haemorrhage | 11.83 | 10.40 | 30 | 83852 | 8113 | 64406737 |
Ejection fraction decreased | 11.72 | 10.40 | 12 | 83870 | 28695 | 64386155 |
Barrett's oesophagus | 11.71 | 10.40 | 9 | 83873 | 766 | 64414084 |
Dysphagia | 11.69 | 10.40 | 86 | 83796 | 106726 | 64308124 |
Dystonia | 11.58 | 10.40 | 5 | 83877 | 18860 | 64395990 |
Oedema peripheral | 11.58 | 10.40 | 198 | 83684 | 210119 | 64204731 |
Vaginal infection | 11.57 | 10.40 | 22 | 83860 | 4898 | 64409952 |
Prostatic specific antigen increased | 11.43 | 10.40 | 31 | 83851 | 8729 | 64406121 |
Increased tendency to bruise | 11.33 | 10.40 | 32 | 83850 | 9223 | 64405627 |
Gait inability | 11.32 | 10.40 | 94 | 83788 | 42274 | 64372576 |
Confusional state | 11.30 | 10.40 | 256 | 83626 | 260888 | 64153962 |
Anxiety | 11.23 | 10.40 | 344 | 83538 | 202305 | 64212545 |
Meralgia paraesthetica | 11.16 | 10.40 | 6 | 83876 | 275 | 64414575 |
Infection | 11.10 | 10.40 | 317 | 83565 | 184563 | 64230287 |
Ligament rupture | 11.02 | 10.40 | 15 | 83867 | 2521 | 64412329 |
Bipolar disorder | 10.98 | 10.40 | 26 | 83856 | 6735 | 64408115 |
Hyperbilirubinaemia | 10.98 | 10.40 | 7 | 83875 | 21198 | 64393652 |
Lower respiratory tract infection | 10.93 | 10.40 | 75 | 83807 | 94539 | 64320311 |
Injection site rash | 10.92 | 10.40 | 45 | 83837 | 15697 | 64399153 |
Sneezing | 10.90 | 10.40 | 44 | 83838 | 15207 | 64399643 |
Vaginal neoplasm | 10.85 | 10.40 | 4 | 83878 | 73 | 64414777 |
Dysphoria | 10.79 | 10.40 | 20 | 83862 | 4368 | 64410482 |
Back disorder | 10.76 | 10.40 | 33 | 83849 | 9957 | 64404893 |
Swelling face | 10.73 | 10.40 | 121 | 83761 | 59045 | 64355805 |
Hepatic cirrhosis | 10.73 | 10.40 | 11 | 83871 | 26287 | 64388563 |
Dysstasia | 10.73 | 10.40 | 59 | 83823 | 23156 | 64391694 |
Lung infiltration | 10.68 | 10.40 | 7 | 83875 | 20882 | 64393968 |
Splenomegaly | 10.65 | 10.40 | 5 | 83877 | 17956 | 64396894 |
Spinal stenosis | 10.61 | 10.40 | 41 | 83841 | 13890 | 64400960 |
Intentional dose omission | 10.59 | 10.40 | 23 | 83859 | 5629 | 64409221 |
Intentional product misuse | 10.58 | 10.40 | 142 | 83740 | 72153 | 64342697 |
Paraesthesia | 10.53 | 10.40 | 239 | 83643 | 134283 | 64280567 |
Dandruff | 10.52 | 10.40 | 6 | 83876 | 309 | 64414541 |
Benign vaginal neoplasm | 10.51 | 10.40 | 4 | 83878 | 80 | 64414770 |
Ear infection | 10.49 | 10.40 | 59 | 83823 | 23345 | 64391505 |
None
Source | Code | Description |
---|---|---|
ATC | M01AC06 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Oxicams |
ATC | M01AC56 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Oxicams |
ATC | N01BB59 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Amides |
FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D052246 | Cyclooxygenase 2 Inhibitors |
MeSH PA | D016861 | Cyclooxygenase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
CHEBI has role | CHEBI:35842 | anti-rheumatic drugs |
CHEBI has role | CHEBI:50629 | COX-2 inhibitor |
FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Osteoarthritis | indication | 396275006 | |
Juvenile rheumatoid arthritis | indication | 410795001 | |
Ankylosing spondylitis | off-label use | 9631008 | DOID:7147 |
Gastritis | contraindication | 4556007 | DOID:4029 |
Alcoholism | contraindication | 7200002 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Body fluid retention | contraindication | 43498006 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Gastrointestinal perforation | contraindication | 51875005 | |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Aortocoronary artery bypass graft | contraindication | 67166004 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Liver function tests abnormal | contraindication | 166603001 | |
Impaired renal function disorder | contraindication | 197663003 | |
Cerebrovascular accident | contraindication | 230690007 | |
Coronary artery bypass graft | contraindication | 232717009 | |
Edema | contraindication | 267038008 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thromboembolic disorder | contraindication | 371039008 | |
Cardiovascular event risk | contraindication | 395112001 | |
Smokes tobacco daily | contraindication | 449868002 |
Species | Use | Relation |
---|---|---|
Cats | Postoperative pain and inflammation associated with orthopedic surgery | Indication |
Cats | Postoperative pain and inflammation associated with ovariohysterectomy | Indication |
Cats | Postoperative pain and inflammation associated with castration | Indication |
Dogs | Pain and inflammation associated with osteoarthritis | Indication |
Product | Applicant | Ingredients |
---|---|---|
Metacam Oral Suspension | Boehringer lngelheim Animal Health USA Inc. | 1 |
Metacam 5 mg/mL Solution for Injection | Boehringer lngelheim Animal Health USA Inc. | 1 |
OroCAM Transmucosal Oral Spray | Zoetis Inc. | 1 |
Meloxicam Injection | Accord Healthcare Inc. | 1 |
Loxicom | Norbrook Laboratories, Ltd. | 1 |
Loxicom | Norbrook Laboratories, Ltd. | 1 |
Meloxicam Solution for Injection | Dechra Veterinary Products LLC | 1 |
Meloxidyl | Ceva Sante Animale | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.65 | acidic |
pKa2 | 5.42 | acidic |
pKa3 | 4.32 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | 8512727 | Dec. 25, 2022 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION |
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | 10463673 | Feb. 24, 2024 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION |
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | 10471067 | Feb. 24, 2024 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION |
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | 10709713 | May 26, 2030 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION |
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | 11253478 | May 26, 2030 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11253504 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9592227 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9913909 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11253504 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9592227 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9913909 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11253504 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9592227 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9913909 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11253504 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9592227 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9913909 | March 13, 2034 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | VIVLODEX | ICEUTICA OPERATIONS | N207233 | Oct. 22, 2015 | DISCN | CAPSULE | ORAL | 9808468 | March 31, 2035 | MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM |
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | VIVLODEX | ICEUTICA OPERATIONS | N207233 | Oct. 22, 2015 | DISCN | CAPSULE | ORAL | 9808468 | March 31, 2035 | MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM |
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | VIVLODEX | ICEUTICA OPERATIONS | N207233 | Oct. 22, 2015 | DISCN | CAPSULE | ORAL | 9808468 | March 31, 2035 | MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM |
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | VIVLODEX | ICEUTICA OPERATIONS | N207233 | Oct. 22, 2015 | DISCN | CAPSULE | ORAL | 9808468 | March 31, 2035 | MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10098957 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10213510 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10632199 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10898575 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083730 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083797 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9694079 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9801945 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10098957 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10213510 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10632199 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10898575 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083730 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083797 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9694079 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9801945 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10098957 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10213510 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10632199 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10898575 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083730 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083797 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9694079 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9801945 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10098957 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10213510 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10632199 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 10898575 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083730 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 11083797 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9694079 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | 9801945 | April 20, 2035 | TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION |
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | 10881663 | March 8, 2039 | MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
30MG/ML (30MG/ML) | ANJESO | BAUDAX | N210583 | Feb. 20, 2020 | RX | SOLUTION | INTRAVENOUS | Feb. 20, 2023 | NEW PRODUCT |
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | May 12, 2024 | NEW PRODUCT |
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | May 12, 2024 | NEW PRODUCT |
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | RX | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | May 12, 2024 | NEW PRODUCT |
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | ZYNRELEF KIT | HERON THERAPS INC | N211988 | May 12, 2021 | DISCN | SOLUTION, EXTENDED RELEASE | PERIARTICULAR | May 12, 2024 | NEW PRODUCT |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 6.80 | CHEMBL | CHEMBL | |||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.85 | CHEMBL | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 6.82 | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 6 | CHEMBL | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 5.86 | CHEMBL |
ID | Source |
---|---|
4021203 | VUID |
N0000148649 | NUI |
D00969 | KEGG_DRUG |
4021203 | VANDF |
C0083381 | UMLSCUI |
CHEBI:6741 | CHEBI |
MXM | PDB_CHEM_ID |
CHEMBL599 | ChEMBL_ID |
DB00814 | DRUGBANK_ID |
D000077239 | MESH_DESCRIPTOR_UI |
54677470 | PUBCHEM_CID |
7220 | IUPHAR_LIGAND_ID |
5615 | INN_ID |
VG2QF83CGL | UNII |
1086708 | RXNORM |
84146 | MMSL |
8839 | MMSL |
d04532 | MMSL |
006272 | NDDF |
125694008 | SNOMEDCT_US |
387055000 | SNOMEDCT_US |
CHEMBL1256873 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-5841 | TABLET | 7.50 mg | ORAL | ANDA | 28 sections |
Mobic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0029 | TABLET | 7.50 mg | ORAL | NDA | 28 sections |
Mobic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0029 | TABLET | 7.50 mg | ORAL | NDA | 28 sections |
Mobic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0030 | TABLET | 15 mg | ORAL | NDA | 28 sections |
Mobic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0030 | TABLET | 15 mg | ORAL | NDA | 28 sections |
MELOXICAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8040 | TABLET | 7.50 mg | ORAL | ANDA | 26 sections |
MELOXICAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8124 | TABLET | 15 mg | ORAL | ANDA | 26 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-052 | TABLET | 15 mg | ORAL | ANDA | 31 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-090 | TABLET | 7.50 mg | ORAL | ANDA | 31 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-251 | TABLET | 15 mg | ORAL | ANDA | 27 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-252 | TABLET | 7.50 mg | ORAL | ANDA | 27 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-555 | TABLET | 15 mg | ORAL | ANDA | 25 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-631 | TABLET | 7.50 mg | ORAL | ANDA | 25 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-925 | TABLET | 15 mg | ORAL | ANDA | 26 sections |
Meloxicam | Human Prescription Drug Label | 1 | 16571-776 | TABLET | 7.50 mg | ORAL | ANDA | 28 sections |
Meloxicam | Human Prescription Drug Label | 1 | 16571-777 | TABLET | 15 mg | ORAL | ANDA | 28 sections |
MELOXICAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-434 | TABLET | 7.50 mg | ORAL | ANDA | 18 sections |
MELOXICAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-469 | TABLET | 15 mg | ORAL | ANDA | 18 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-076 | TABLET | 7.50 mg | None | ANDA | 26 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-077 | TABLET | 15 mg | ORAL | ANDA | 26 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-124 | TABLET | 7.50 mg | ORAL | ANDA | 27 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-125 | TABLET | 15 mg | ORAL | ANDA | 27 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-070 | TABLET | 7.50 mg | ORAL | ANDA | 25 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-071 | TABLET | 15 mg | ORAL | ANDA | 25 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-808 | TABLET | 7.50 mg | ORAL | ANDA | 25 sections |
meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-808 | TABLET | 7.50 mg | ORAL | ANDA | 25 sections |
Vivlodex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42211-205 | CAPSULE | 5 mg | ORAL | NDA | 28 sections |
Vivlodex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42211-206 | CAPSULE | 10 mg | ORAL | NDA | 28 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-519 | TABLET | 15 mg | ORAL | ANDA | 27 sections |
Meloxicam | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-604 | TABLET | 7.50 mg | ORAL | ANDA | 27 sections |